HI (n = 38) | MS (n = 90) | p value | |
---|---|---|---|
Female, n (%) | 25 (67) | 66 (73) | 0.387 |
Baseline age (yrs); mean (SD) | 45.1 (13.6) | 47.3 (10.4) | 0.309 |
Time to F/up (yrs); mean (SD) | 5.4 (0.3) | 5.5 (0.5) | 0.342 |
Baseline BMI (kg/m2); mean (SD) | 26.6 (5.8) | 27.7 (5.9) | 0.363 |
Follow-up BMI (kg/m2); mean (SD) | 26.2 (5.2) | 27.9 (5.9) | 0.363 |
Baseline comorbidities, n (%) | |||
Hypertension | 6 (16) | 11 (12) | 0.586 |
Hyperlipidemia | 6 (16) | 11 (12) | 0.586 |
Diabetes | 2 (5) | 2 (4) | 0.372 |
Follow-up comorbidities, n (%) | |||
Hypertension | 9 (24) | 15 (17) | 0.353 |
Hyperlipidemia | 10 (26) | 22 (23) | 0.719 |
Diabetes | 3 (8) | 4 (4) | 0.433 |
Baseline disease duration (yrs), mean (SD) | N/A | 15.3 (10.0) | N/A |
Disease progression, n (%) | |||
CIS → RR | N/A | 7 (8) | N/A |
RR → SP | 11 (13) | ||
Remained RR | 46 (51) | ||
SP since baseline | 27 (30) | ||
Baseline EDSS, median (IQR) | N/A | 3.0 (1.5–5.5) | N/A |
F/up EDSS, median (IQR) | N/A | 3.5 (2.0–6.0) | N/A |
∆EDSS, mean (SD); median | N/A | 0.3 (0.9); 0.5 | N/A |
DP at F/up, n (%) | N/A | 25 (28) | N/A |
Annualized relapse rate at F/up, mean (SD) | N/A | 0.2 (0.4) | N/A |
Relapse free from baseline to follow-up, n (%) | N/A | 55 (61) | N/A |
Baseline DMT status, n (%) | |||
Interferon-beta 1a | N/A | 34 (38) | N/A |
Glatiramer acetate | 20 (22) | ||
Natalizumab | 18 (20) | ||
Other DMT* | 4 (4) | ||
No DMT | 14 (16) | ||
Follow-up DMT status, n (%) | |||
Remained on same DMT | N/A | 47 (52) | N/A |
Switched to another DMT | 33 (37) | ||
No DMT | 10 (11) |